Johnson & Johnson reports Q2 revenue of $25.31B, topping estimates, but shares fall over 2% in afternoon trading.
Johnson & Johnson posted second-quarter revenue of $25.31 billion, up 6.6% year over year and above the LSEG consensus of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the $2.85 estimate. The company also raised its full-year guidance.
Despite the earnings beat, JNJ shares declined over 2% in afternoon trading. Historically, the stock has shown muted reactions to earnings, averaging less than a 1% move since Q3 2021. The company’s performance reflects consistent execution, though recent market rotations have impacted defensive stocks.
Healthcare stocks, including JNJ, fell out of favor during the AI-driven market rally earlier this year but regained some ground in June as the trade wobbled. The stock’s recent pullback aligns with broader sector trends.